Resource Library

14 July 2022

Tanzania National Guidelines for Comprehensive Package of HIV Interventions for Key & Vulnerable Populations, 2017

With the global 2030 goal to eliminate HIV, the Government of Tanzania is working to support those most in need of HIV prevention and treatment services. These national guidelines standardize the implementation of a comprehensive HIV prevention and treatment services for Key and Vulnerable Populations (KVP).

Normative Guidance/Policies

14 July 2022

Social and Behaviour Change Communication Strategy for Sexual & Reproductive Health, Rights & HIV in Lesotho 2020-21 to 2022-23

Lesotho's Social and Behaviour Change Communication Strategy is a strategic response to the high levels of HIV and TB prevalence in the country that are exacerbated by the persistence of structural and sio-economic difficulties, such as poverty, unemployment, gender inequality and more. This strategy aims to address these issues.

Research, Normative Guidance/Policies

Synthesis of Post-Exposure Prophylaxis (PEP) Policies in MOSAIC Countries

This brief summarizes the PEP policy landscape, how to address barriers to policy and implementation, and provides recommendations to increase PEP uptake as part of HIV prevention. While it focuses on countries within the MOSAIC consortium, the findings are broadly applicable for ministries of health, implementing partners, providers, and potential PEP users alike.

Normative Guidance/Policies

FDA approves first drug for reducing the risk of sexually acquired HIV infection

This article from July 16, 2012 announces the U.S. Food and Drug Administration's approval of Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners.

Normative Guidance/Policies

WHO PrEP Implementation Tool App

The Oral PrEP eLearning Resource Package (eLRP) introduces health care providers to Oral PrEP for HIV infection. The eLRP includes eLearning courses for clinicians with an accompanying Oral PrEP Implementation Tool App.

Normative Guidance/Policies

Descovy for PrEP

The U.S. Food and Drug Administration has reported that they have approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) who at at risk of acquiring HIV.

Normative Guidance/Policies

FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic

This article announces the U.S. Food and Drug Administration's approval of Descovy in at-risk adults and adolescents for HIV pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection from sex, excluding those who have receptive vaginal sex.

Normative Guidance/Policies

Descovy for PrEP – FDA Supplemental Approval

This letter from the US Food and Drug Administration outlines supplemental approval granted to Descovy, an oral PrEP medication.

Normative Guidance/Policies

Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach

These consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring bring together existing and new clinical and programmatic recommendations across different ages, populations and settings, bringing together all relevant WHO guidance on HIV produced since 2016. It serves as an update to the previous edition of the consolidated guidelines on HIV.

Normative Guidance/Policies, Service Delivery